Expert Witness Blog
In the recent case of Eike v. Allergan, Inc., 7th Cir. 2017, the United States Court of Appeals for the Seventh Circuit addressed the admissibility and impact of testimony from an Antitrust Expert Witness in a class action alleging anticompetitive conduct by pharmaceutical manufacturers. This case exemplifies the critical role of expert economic analysis in antitrust litigation and the rigorous scrutiny such testimony faces under the Daubert standard.
Background and Parties
The plaintiffs, representing eight certified classes of consumers in Illinois and Missouri, alleged that six pharmaceutical companies, including Allergan, Inc., manufactured glaucoma eye drops in unnecessarily large sizes. Plaintiffs claimed this practice was wasteful, increased costs, and constituted a violation of state consumer protection statutes. The defendants countered that the size of the eye drops was medically justified and approved by the FDA.
Role and Methods of the Antitrust Expert Witness
Central to the plaintiffs’ case was the testimony of an Antitrust Expert Witness, an economist retained to analyze whether the defendants’ conduct resulted in anticompetitive harm and economic injury to consumers. The expert employed econometric models and market analysis to argue that the oversized eye drops led to supracompetitive pricing and consumer harm, supporting the plaintiffs’ theory of antitrust injury and damages.
The expert’s methodology included:
– Defining the relevant product and geographic markets for prescription eye drops.
– Assessing the competitive dynamics among pharmaceutical manufacturers.
– Calculating alleged overcharges and quantifying consumer harm based on the difference between actual and hypothetical competitive pricing.
Daubert Reliability Analysis
The district court, acting as gatekeeper under Daubert v. Merrell Dow Pharmaceuticals, Inc., rigorously examined the reliability and relevance of the expert’s testimony. The court evaluated whether the expert’s methods were scientifically valid, properly applied to the facts of the case, and based on sufficient data. Key factors considered included:
– Whether the expert’s market definition aligned with accepted economic principles.
– The robustness of the econometric models and the validity of underlying assumptions.
– The connection between the alleged conduct and measurable economic harm to the class.
The court found that, while the expert’s testimony was methodologically sound in its use of standard economic tools, it ultimately failed to establish a concrete injury to the plaintiffs. The expert could not demonstrate that any class member had actually suffered harm, as required for standing under Article III. The court noted that the FDA had approved the eye drops’ size for safety and efficacy, and there was no evidence of misrepresentation or collusion among the defendants.
Impact of Expert Testimony on the Outcome
The exclusion of the expert’s damages and injury analysis was pivotal. Without admissible expert testimony establishing actual harm, the plaintiffs’ claims could not proceed. The Seventh Circuit vacated the class certification and instructed the district court to dismiss the case, emphasizing that disappointment with product design, absent a cognizable injury, does not confer standing. The court’s decision underscores the indispensable role of the Antitrust Expert Witness in substantiating both liability and damages in complex antitrust litigation.
This case illustrates the heightened scrutiny applied to antitrust expert testimony under Daubert, particularly regarding the necessity of demonstrating actual economic injury. The outcome reaffirms that expert analysis must not only be methodologically rigorous but also directly tied to the legal elements of antitrust claims, especially injury and causation. The court’s approach in Eike v. Allergan, Inc. serves as a benchmark for future antitrust cases involving expert economic evidence and the critical gatekeeping function of the judiciary.